Literature DB >> 7436516

Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.

A J Martin, C A Smalley, R H George, D E Healing, C M Anderson.   

Abstract

18 children with cystic fibrosis and mucoid pseudomonas lung infection were treated with courses either of gentamicin plus carbenicillin, or tobramycin plus carbenicillin, with 2 children each receiving two courses. 10 courses of gentamicin at a dose of 9 mg/kg per day plus carbenicillin at 800 mg/kg per day, and 10 courses of tobramycin at 9 mg/kg per day plus carbenicillin at 800 mg/kg per day were given. There was clinical and x-ray improvement in both groups of children, but there was no difference between the therapeutic benefit of either regimen. Pseudomonas aeruginosa was not cultured at the end of treatment after 15 of the 20 courses, but it returned in all but one patient within 3 months. Neither ototoxicity nor renal damage with these high doses of aminoglycoside was detected. P. aeruginosa had not been eliminated when 9 of these patients earlier had received courses of gentamicin in a dose of 6 mg/kg per day plus carbenicillin at 800 mg/kg per day. The results show that P. aeruginosa can successfully be eliminated or suppressed with high-dose aminoglycoside plus carbenicillin, but such elimination is usually short lived.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7436516      PMCID: PMC1627058          DOI: 10.1136/adc.55.8.604

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  14 in total

1.  Pyocine typing of mucoid strains of Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Authors:  R J Williams; J R Govan
Journal:  J Med Microbiol       Date:  1973-08       Impact factor: 2.472

2.  Bacterial precipitins in serum of patients with cystic fibrosis.

Authors:  M W Burns; J R May
Journal:  Lancet       Date:  1968-02-10       Impact factor: 79.321

3.  Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71.

Authors:  M B Mearns; G H Hunt; R Rushworth
Journal:  Arch Dis Child       Date:  1972-12       Impact factor: 3.791

4.  Treatment and prevention of pulmonary complications of cystic fibrosis in infancy and early childhood.

Authors:  M B Mearns
Journal:  Arch Dis Child       Date:  1972-02       Impact factor: 3.791

5.  Tobramycin therapy of pulmonary infections in patients with cystic fibrosis.

Authors:  H B Hawley; R M Lewis; D R Swartz; D W Gump
Journal:  Curr Ther Res Clin Exp       Date:  1974-05

6.  Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  G E Hoff; P O Schiotz; J Paulsen
Journal:  Scand J Infect Dis       Date:  1974

7.  Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-08

8.  Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-08

9.  Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections.

Authors:  M I Marks; R Prentice; R Swarson; E K Cotton; T C Eickhoff
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

10.  Carbenicillin in patients with cystic fibrosis: clinical pharmacology and therapeutic evaluation.

Authors:  N N Huang; E J Hiller; C M Macri; M Capitanio; K R Cundy
Journal:  J Pediatr       Date:  1971-02       Impact factor: 4.406

View more
  5 in total

Review 1.  Cystic fibrosis, pathophysiological and clinical aspects.

Authors:  H J Neijens; M Sinaasappel; R de Groot; J C de Jongste; S E Overbeek
Journal:  Eur J Pediatr       Date:  1990-08       Impact factor: 3.183

2.  Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis.

Authors:  Sally Palser; Sherie Smith; Edward F Nash; Arnav Agarwal; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

3.  Pharmacokinetics of amikacin in cystic fibrosis: a study of bronchial diffusion.

Authors:  E Autret; S Marchand; M Breteau; B Grenier
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis.

Authors:  T L Pitt
Journal:  J R Soc Med       Date:  1986       Impact factor: 18.000

Review 5.  Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Authors:  Matthew N Hurley; Andrew P Prayle; Patrick Flume
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.